autologous CD19-directed chimeric antigen receptor (CAR) T-cells clinical trials

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

This study looks at a new treatment called CAR T-cell therapy for people aged 2-70 with aggressive lymphoma or acute leukaemia that has come back. It involves modifying your own immune cells to fight cancer, after a short course of chemotherapy.